Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
2020 · Oncogene · 179 citations
https://doi.org/10.1038/s41388-020-1328-y
E
Emma Dean
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
284
Papers
5.5K
Citations
37
h-index
84
i10-index
Emma Dean is an academic researcher from AstraZeneca (United Kingdom). The author has contributed to research in topics: PARP inhibition in cancer therapy & DNA Repair Mechanisms & Lung Cancer Treatments and Mutations. The author has an h-index of 37, co-authored 242 publications.
ORCID: 0000-0001-9956-257XPapers by this author
worksA phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors
2016 · Annals of Oncology · 141 citations
https://doi.org/10.1093/annonc/mdw427
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
2021 · British Journal of Cancer · 114 citations
https://doi.org/10.1038/s41416-021-01405-x
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers
2018 · British Journal of Cancer · 107 citations
https://doi.org/10.1038/s41416-018-0082-1
Multi-level evidence that circulating CK18 is a biomarker of tumour burden in colorectal cancer
2012 · British Journal of Cancer · 38 citations
https://doi.org/10.1038/bjc.2012.416
Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
2022 · npj Breast Cancer · 37 citations
https://doi.org/10.1038/s41523-022-00406-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat